Clinical trials: Kidney Transplant Recipients
Kidney Failure, Kidney Transplant
Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)
This research study is for patients who are going to receive a kidney transplant from a living donor. After kidney transplantation, it is necessary for transplant recipients to take "immunosuppressive drugs".
- Trial name
- NCT02091232
- Testing
- T Regulatory Cell Infusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Transplant; Failure, Kidney
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
The purpose of this study is to assess Alefacept in combination with alemtuzumab induction and calcineurin inhibitor and corticosteroid withdrawal.
- Trial name
- NCT01163799
- Testing
- Alefacept (ASP0485)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Renal Transplantation
Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
The aim of the study is to assess the short-term benefit of the combination of basiliximab, EC-MPS and cyclosporine microemulsion with C2 monitoring on the prophylaxis of acute rejection in a population of de novo renal…
- Trial name
- NCT00154232
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Kidney Transplant Infection, Bloodstream Infection
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation
Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs).
- Conditions
- Kidney Transplant Infection, Bloodstream Infection, Kidney Transplant, Kidney Transplant Recipients
- Trial name
- PREDICT (NCT07407673)
- Testing
- Pivmecillinam
- Where
- 3 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- Susanne Dam Nielsen, MD, DMSc
Renal Transplantation
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
To compare renal allograft rejection rates during the first year among high-immunological risk recipients between patients who received either ATG or the anti-IL2R mAb daclizumab.
- Trial name
- TAXI (NCT00682292)
- Testing
- Thymoglobulin (ATG), Daclizumab
- Where
- France
- Volunteers
- 227 people
- Sponsor
- University Hospital, Lille
Transplant Recipient (Kidney), Primary Kidney Transplantation
Posttranslationally Modified Fetuin-A in Urine as a Marker for Renal Dysfunction (Patients With Chronic Kidney Disease - With or Without Kidney Transplantation).
Kidney transplantation is the preferred treatment method for patients with chronic kidney disease. Standard parameters (estimated glomerular filtration, albuminuria) of renal function detection are limited by many factors…
- Trial name
- (uPTM-FetA) (NCT06950931)
- Testing
- uPTM-FeA
- Where
- Slovakia
- Volunteers
- 86 people
- Sponsor
- University Hospital, Martin
Highly Sensitized Prospective Kidney Transplant Recipients
Carfilzomib and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ADAPT (NCT05017545)
- Testing
- carfilzomib, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation
Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
Imlifidase is a recombinant cysteine protease derived from Streptococcus pyogenes and produced in Escherichia coli, which has the ability to cleave and degrade all human IgGs.
- Trial name
- ISKIA (NCT07379957)
- Where
- 20 sites in France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Bordeaux
End-Stage Renal Disease
Steroid Withdrawal in Pediatric Kidney Transplant Recipients
The purpose of this study is to examine the effects of withdrawing steroids on graft rejection and kidney functions in kidney transplant recipients between the ages of 0 and 20 years (prior to their 21st birthday).
- Trial name
- NCT00023244
- Testing
- Basiliximab, Cyclosporine, Tacrolimus
- Where
- 19 sites in United States, Mexico
- Volunteers
- 274 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipients
Envarsus XR Compared to Immediate Release Tacrolimus
The purpose of this study is to compare once-daily tacrolimus extended-release (Envarsus XR®) to twice-daily immediate release tacrolimus to find out if people taking tacrolimus extended release (Envarsus XR®) report fewer side…
- Trial name
- SIMPLE (NCT03979365)
- Testing
- Envarsus XR, Tacrolimus twice daily
- Where
- 3 sites in United States
- Volunteers
- 261 people
- Sponsor
- Mayo Clinic
Postoperative Renal Function
Intraoperative Laser Speckle Imaging Predicts Early Renal Function After Kidney Transplantation
This observational study aims to explore the predictive value of intraoperative laser speckle contrast imaging for early postoperative renal function in kidney transplant recipients.
- Trial name
- NCT07753434
- Testing
- laser speckle contrast imaging (LSCI)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Renal Transplant
Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients
Primary objectives: A. To evaluate the effect of Zortress® versus standard immunosuppression therapy on progression of CAC as evidenced by changes in Agatston scores from baseline and at 6, and 12 months in renal transplantation…
- Trial name
- NCT01612299
- Testing
- Zortress® /Everolimus
- Where
- United States
- Sponsor
- University of Kentucky
Transplantation, Kidney, Living Donors
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
The aim of this study is to determine a comprehensive immune profile of transplant donors and recipients through assessment of immune cell compositions in bone marrow, and lymph nodes.
- Conditions
- Transplantation, Kidney, Living Donors, Kidney Transplant Recipients
- Trial name
- NCT01150487
- Testing
- bone marrow aspirations, lymph node collection
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Mayo Clinic
Kidney Transplantation
Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.
Primary objective of this study is to compare the renal function as well as the incidence of renal dysfunction, the incidence of death, graft loss and acute rejection.
- Trial name
- SENIOR (NCT00296309)
- Testing
- Tacrolimus
- Where
- 33 sites in Belgium, France and 5 more
- Volunteers
- 267 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplantation
A Dose Escalation Study in de Novo Renal Transplantation
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
- Trial name
- NCT04311632
- Testing
- TCD601, Tacrolimus (TAC), Corticosteroids (CS)
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- ITB-Med LLC
CYCLOSPORINE/TACROLIMUS
The Effects of Conversion From Cyclosporine to Tacrolimus on the Changes of Cardiovascular Risk Profiles and Serum Metabolites in Renal Transplant Recipients
The purpose of this study is to evaluate the effects of conversion from cyclosporine to tacrolimus on the changes of cardiovascular risk profiles and serum metabolites in renal transplant recipients.
- Trial name
- NCT02496494
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Kyungpook National University Hospital
Renal Transplant Recipient
Abatacept Conversion in Kidney Transplantation
This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has been developed to answer the question: Can patients be safely converted from monthly belatacept IV infusions to abatacept subcutaneous…
- Trial name
- NCT04955366
- Testing
- Belatacept, Abatacept
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Emory University
Urinary Tract Infections, Kidney Transplant Rejection
PRObiotics for KIdney Transplantation
The goal of this clinical trial is to assess if dietary supplememtation with OMNi-BiOTiC® 41167 reduces the risk of urinary tract infections in kidney transplant recipients.
- Conditions
- Urinary Tract Infections, Kidney Transplant Rejection, Kidney Transplant Infection, Dysbiosis
- Trial name
- ProKiT (NCT06825117)
- Testing
- OMNi-BiOTiC® 41167
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- University Hospital, Udine, Italy